Minerva stumbles with U.S. application for schizophrenia med; shares down 15%

Minerva Neurosciences (NASDAQ:NERV) slumps 15% premarket on increased volume in reaction to its receipt of minutes from a recent meeting with the FDA regarding the data package supporting its planned marketing application seeking approval of roluperidone for the treatment of negative symptoms of schizophrenia.